<DOC>
	<DOCNO>NCT02431312</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability , immunogenicity dose combination INO-1800 ( DNA plasmid encode HBsAg HBcAg ) INO-9112 ( DNA plasmid encode human interleukin 12 ) deliver electroporation ( EP ) 90 ( ninety ) nucleos ( ) ide analogue treat patient .</brief_summary>
	<brief_title>Phase I Study INO-1800 With Without INO-9112 + EP Chronic Hepatitis B Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>INCLUSION CRITERIA : Chronic Hepatitis B virus infection Negative Hepatitis A IgM , C , D HIV Liver biopsy , Fibroscan® equivalent elastographybased test obtain within past 6 mon demonstrate liver disease without evidence bridge fibrosis cirrhosis support platelet count great central laboratory LLN screen Positive Hepatitis B surface antigen Nucleos ( ) ide treatment least 1 year ongoing nucleos ( ) ide analogue treatment randomization HBV DNA &lt; 90 IU/mL ≥6 mon prior randomization Screening laboratory value within normal range ALT ≤1.5x ULN 2 measurement separate least 14 day 6 mon prior randomization ALT screen ≤1.5x ULN AST , TBili , DBili , GGT , Alk Phos albumin within normal range judge clinically significant PI medical monitor screen For men woman postmenopausal [ i.e . ≥ 12 month nontherapyinduced amenorrhea , confirm follicle stimulate hormone ( FSH ) , hormone replacement ] surgically sterile ( vasectomy male absence ovary and/or uterus female ) agreement remain abstinent use 1 highly effective combine contraceptive method result failure rate &lt; 1 % per year treatment period least week 12 last dose EXCLUSION CRITERIA : Pregnant breastfeeding female Positive serum pregnancy test screen positive urine pregnancy test randomization Use topical corticosteroid near intend administration site Autoimmune disorder , transplant recipient , immunosuppression include concurrent condition require use immunosuppressive/immunomodulating agent ( eye dropcontaining infrequent inhale corticosteroid permissible ) Need systemic antiviral treatment ( chronic hepatitis B infection ) Documented history evidence decompensated liver disease ( e.g. , ascites , bleed esophageal varix , ChildPugh clinical classification B C ) ; History evidence medical condition associate chronic liver disease [ e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , nonalcoholic steatohepatitis ( NASH ) , toxin exposure , thalassemia , etc . ] Documented history evidence metabolic liver disease within 1yr randomization Abnormal renal function include serum creatinine &gt; ULN calculate creatinine clearance &lt; 70 mL/min ( use Cockcroft Gault formula ) History suspicion HCC Screening alpha fetoprotein great 13 ng/mL Prior history current malignancy adequately treat BCC , unless history BCC near dintended administration site History significant medical condition [ e.g. , cardiac ( include ventricular supraventricular arrhythmia ) , renal disease , pulmonary , gastrointestinal , neurological ] Significant acute infection ( e.g. , influenza , local infection ) clinically significant illness within 2 week randomization Administration blood product within 3 mon randomization History seizure ( unless seizure free 5yrs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic HBV</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>electroporation</keyword>
</DOC>